RNS Number : 1148L
Kromek Group PLC
03 June 2025

3 June 2025

Kromek Group plc
("Kromek" or the "Group")

Capital Markets Day

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that it will be hosting a capital markets day (the "CMD") on Wednesday 18 June 2025 for institutional investors and analysts.

Arnab Basu, CEO, Claire Burgess, CFO, and Berry Beumer, President of Advanced Imaging, alongside key members of Kromek's management team and external industry representatives will host an in-person event to outline the Group's strategy and prospects for delivering the next stage of growth.

The CMD will take place at the offices of Cavendish Capital Markets at One Bartholomew Close, London, EC1A 7BL. Registration is from 2.00pm with the presentations scheduled to run from 2.15pm to 4.15pm followed by Q&A.

Institutional investors and analysts wishing to attend the CMD should register their interest by emailing ir@cavendish.com.

Retail Investor Webinar

The Group will also be hosting an online Q&A session for retail investors at 5.00pm on Wednesday 25 June 2025 on the Investor Meet Company platform. A recording of the CMD and the presentations will be made available on the Group's website as well as on the Investor Meet Company platform in advance of the webinar.

Questions can be submitted pre-webinar via the Investor Meet Company platform up until 9.00am on 23 June 2025 or at any time during the live webinar. Investors can sign up to Investor Meet Company for free and register to attend the Kromek Q&A session via:
https://www.investormeetcompany.com/kromek-group-plc/register-investor

Kromek Group plc
Arnab Basu, CEO — +44 (0)1740 626 060
Claire Burgess, CFO

Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance — +44 (0)20 7220 0500
Tim Redfern - ECM
Michael Johnson - Sales

Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury/Henry Gamble — +44 (0)20 4582 3500

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has

manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLLLBEQLLBBK